CLINICAL GUIDELINES FOR DIAGNOSTICS AND EARLY INTERVENTION IN PRIMARY ALDOSTERONISM
RESEARCHER PROFILE
Associate Professor Jun Yang (Filmed May 2024)
Head of Endocrine Hypertension Group, Hudson Institute of Medical Research
Consultant Endocrinologist at Monash Health &
Senior Researcher in Department of Medicine at Monash University, Victoria, Australia
Associate Professor Jun Yang is the Head of the Endocrine Hypertension Group at Hudson Institute of Medical Research, Consultant Endocrinologist at Monash Health and Senior Researcher in the Department of Medicine at Monash University, Victoria, Australia.
Yang graduated from Monash University with a MBBS (Hon) in 2001, obtained the FRACP in 2010 and completed her PhD on tissue-selective coregulators of the mineralocorticoid receptor (MR) in 2013.
She has continued basic and clinical research in the field of MR-driven cardiovascular disease, in particular, primary aldosteronism. Primary Aldosteronism (PA), or Conn Syndrome, is the most commonly under-diagnosed cause of high blood pressure affecting millions of people. Jun’s goal is to facilitate the diagnosis of every case of PA and make treatment widely available to all communities including the disadvantaged.
She established the Endocrine Hypertension Service in 2016 and co-leads the NHMRC Centre of Research Excellence in Primary Aldosteronism.
“My main interest lies in the translation of primary aldosteronism research into revised clinical guidelines, improved diagnostic tools and transformed practice to help patients. In addition, I am identifying the earliest point of disease occurrence with the aim of enabling earlier intervention and return to health”, says Associate Professor Yang.
Together with national and international collaborators, her research program seeks to improve the detection and understanding of primary aldosteronism to achieve improved patient outcomes.
-
Role of metabolic dysfunction in advanced prostate cancer
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
-
Anaemia guidelines updated after 50 years
Professor Sant-Rayn Pasricha is the Acting Deputy Director at the Walter Eliza Hall Institute of Medical Research in Melbourne, Australia. He is also a clinical haematologist at the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. From a young age, Prof Pasricha dreamed of becoming a doctor and found joy in learning about the human body and how to care for patients. After completing medical school, he developed a passion for working in low and middle-income countries, which led him to spend time working in East Timor, India, and Central Australia with First Nations communities.
-
Cancer survivorship and exercise oncology
Professor Sandra Hayes is the Director of Research at Cancer Council Queensland (CCQ), where she leads a comprehensive cancer research program encompassing cancer epidemiology, prevention, detection, treatment, and survivorship.
With a BAppSci (Hons) and a PhD in exercise oncology, Professor Hayes’s expertise lies in quantifying the impact of cancer diagnosis and treatment on physical and psychosocial wellbeing, quality of life, and survival. She also evaluates innovative supportive care strategies, particularly exercise, to improve post-cancer lives.
